Volume 44 | Number 6 | December 2009

Abstract List

Peter A. Newman, Sung‐Jae Lee, Naihua Duan, Ellen Rudy, Terry K. Nakazono, John Boscardin, Lisa Kakinami, Steven Shoptaw, Allison Diamant, William E. Cunningham


To assess HIV vaccine acceptability among high‐risk adults in Los Angeles.

Study Setting

Sexually transmitted disease clinics, needle/syringe exchange programs, Latino community health/HIV prevention programs.

Study Design

Cross‐sectional survey using conjoint analysis. Participants were randomly selected using three‐stage probability sampling.

Data Collection

Sixty‐minute structured interviews. Participants rated acceptability of eight hypothetical vaccines, each with seven dichotomous attributes, and reported post‐vaccination risk behavior intentions.

Principal Findings

Participants (=1164; 55.7 percent male, 82.4 percent ethnic minority, mean age=37.4 years) rated HIV vaccine acceptability from 28.4 to 88.6; mean=54.5 (SD=18.8; 100‐point scale). Efficacy had the greatest impact on acceptability, followed by side effects and out‐of‐pocket cost. Ten percent would decrease condom use after vaccination.


Findings support development of social marketing interventions to increase acceptability of “partial efficacy” vaccines, behavioral interventions to mitigate risk compensation, and targeted cost subsidies.